Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 10, 2019 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Bank of America Merrill Lynch Health Care Conference

RESEARCH TRIANGLE PARK, N.C., May 10, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America Merrill Lynch Health...
May 09, 2019 16:15 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Completes Phase 1 Clinical Trial of Galidesivir

RESEARCH TRIANGLE PARK, N.C., May 09, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the completion of a randomized, placebo-controlled Phase 1 clinical trial...
May 08, 2019 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports First Quarter 2019 Financial Results

—Phase 3 APeX-2 24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019— —Phase 3 ZENITH-2 trial of oral BCX7353 for...
May 06, 2019 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., May 06, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
April 24, 2019 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Report First Quarter 2019 Financial Results on May 8

RESEARCH TRIANGLE PARK, N.C., April 24, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2019 financial results...
April 01, 2019 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., April 01, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the H.C. Wainwright Global Life...
March 04, 2019 07:02 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports Fourth Quarter and Full Year 2018 Financial Results

—APeX-2 24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019— —Full ZENITH-1 results confirm safety and efficacy...
March 04, 2019 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development

—BCX9930 shows high potency, specificity, suppression of hemolysis and wide safety margin in preclinical studies— —Could address multiple complement-mediated diseases of the kidney, blood and nervous...
February 28, 2019 07:00 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst to Present at Barclays Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Barclays Global Healthcare...
February 23, 2019 12:45 ET | Source: BioCryst Pharmaceuticals, Inc.

BioCryst Reports ZENITH-1 Results With Oral BCX7353 Which Confirm Rapid Onset of Action, Sustained Activity and Robust Dose Response for Treatment of Acute HAE Attacks

—Based on ZENITH-1 data, company plans to commence Phase 3 trial of single-dose 750 mg oral BCX7353 for acute treatment of hereditary angioedema (HAE) attacks in summer 2019— —Data show excellent...